Alpha Cubed Investments’s Neurocrine Biosciences NBIX Stock Holding History

Alpha Cubed Investments’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-36,000	Closed	-$4.03M	–	281
2018 Q3	$4.03M	Hold	36,000	–	–	0.47%	54
2018 Q2	$3.54M	Hold	36,000	–	–	0.46%	53
2018 Q1	$2.98M	Hold	36,000	–	–	0.39%	57
2017 Q4	$2.79M	Hold	36,000	–	–	0.36%	58
2017 Q3	$2.21M	Hold	36,000	–	–	0.33%	61
2017 Q2	$1.66M	Hold	36,000	–	–	0.28%	60
2017 Q1	$1.56M	Hold	36,000	–	–	0.32%	53
2016 Q4	$1.39M	Hold	36,000	–	–	0.33%	58
2016 Q3	$1.82M	Hold	36,000	–	–	0.49%	45
2016 Q2	$1.64M	Hold	36,000	–	–	0.56%	40
2016 Q1	$1.42M	Hold	36,000	–	–	0.43%	51
2015 Q4	$2.04M	Hold	36,000	–	–	0.53%	52
2015 Q3	$1.77M	Hold	36,000	–	–	0.46%	54
2015 Q2	$1.72M	Hold	36,000	–	–	0.46%	61
2015 Q1	$1.43M	Buy	+36,000	New	+$1.29M	0.45%	59

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Alpha Cubed Investments's NBIX Position: Q4 2018 in Review

Alpha Cubed Investments sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 36,000 shares — an estimated $4.03M sold.

Alpha Cubed Investments first reported a position in NBIX in Q1 2015 and held it in 15 quarters. The position peaked at $4.03M in Q3 2018. 331 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

Alpha Cubed Investments reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
Alpha Cubed Investments sold 36,000 Neurocrine Biosciences shares in Q4 2018, an estimated $4.03M.
Alpha Cubed Investments first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 15 quarters.
Alpha Cubed Investments's Neurocrine Biosciences position peaked at $4.03M in Q3 2018.
331 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Alpha Cubed Investments's 13F filing for Q4 2018, filed 29 Jan 2019.